Format

Send to

Choose Destination
J Neuroimmunol. 2018 Feb 15;315:28-32. doi: 10.1016/j.jneuroim.2017.12.012. Epub 2017 Dec 18.

Complex HLA association in paraneoplastic cerebellar ataxia with anti-Yo antibodies.

Author information

1
Center for Sleep Sciences and Medicine, Stanford University, 3165 Porter Drive, Palo Alto, CA 94304, USA.
2
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Hôpital Neurologique, F-69677 Bron, France; Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon - Université Claude Bernard Lyon 1, F-69372 Lyon, France.
3
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Hôpital Neurologique, F-69677 Bron, France.
4
Unité du Sommeil, CHRU Gui de Chauliac, National Reference Centre for Orphan Diseases, Narcolepsy, Idiopathic Hypersomnia, 80 avenue Augustin Fliche, 34295, Montpellier Cedex 5, INSERM U1061, Montpellier, France.
5
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Hôpital Neurologique, F-69677 Bron, France; Institut NeuroMyoGene INSERM U1217/CNRS UMR 5310, Université de Lyon - Université Claude Bernard Lyon 1, F-69372 Lyon, France. Electronic address: jerome.honnorat@chu-lyon.fr.
6
Center for Sleep Sciences and Medicine, Stanford University, 3165 Porter Drive, Palo Alto, CA 94304, USA. Electronic address: mignot@stanford.edu.

Abstract

Anti-Yo paraneoplastic cerebellar degeneration (PCD) is a devastating autoimmune complication of gynecological cancers. We hypothesized that as for other autoimmune diseases, specific HLA haplotypes are associated. We conducted high resolution HLA typing of Class I/Class II in 40 cases versus ethnically matched controls. Three cases with anti-Yo antibodies and peripheral neuropathy were also included. We detected protective effects of DPA1*01:03~DPB1*04:01 (OR=0, p=0.0008), DRB1*04:01~DQA1*03:03(OR=0, p=0.0016) and DPA1*01:03~DPB1*04:01 (OR=0.35, p=0.0047) overall. Increased DRB1*13:01~DQA1*01:03~DQB1*06:03 was also found in PCD ovarian cases (OR=5.4, p=0.0016). These results suggest differential genetic susceptibility to anti-Yo per cancer and with a primary HLA Class II involvement.

KEYWORDS:

Anti-Yo; Ataxia; Breast cancer; Ovarian cancer; Paraneoplastic

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center